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Purpose: The polymorphisms of the Fc receptor-like 3 gene (FCRL3), a novel immunoregulatory gene, have been shown
to be associated with certain autoimmune diseases. This study was designed to examine whether the polymorphisms of
FCRL3 are associated with susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Chinese population.
Methods: A case-control study was performed in 230 Chinese VKH patients and 301 healthy controls. Four single
nucleotide  polymorphisms  (SNPs;  −169C/T,  −110A/G,  +358C/G,  and  +1381A/G)  in  FCRL3  were  detected  using
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). human leukocyte antigen -DR4 (HLA-
DR4) and HLA-DRw53 genotyping was performed using PCR techniques.
Results: The results showed that the frequency of haplotype CACG was significantly lower in patients when compared
with that in controls (p=0.0018, corrected p [pc]=0.0288). A significantly higher frequency was found for haplotype CGGG
in HLA-DR4 negative patients than in HLA-DR4 negative controls (p=9.94×10−8, Pc=1.59×10−6). There were no significant
differences in the allele and genotype frequencies of the four investigated SNPs between VKH patients and controls. HLA-
DR4 and HLA-DRw53 were significantly associated with VKH syndrome (p=3.21×10−16 and p=7.08×10−5, respectively).
Stratification analysis according to HLA-DR4 and HLA-DRw53 did not show any association of FCRL3 polymorphisms
with VKH syndrome.
Conclusions: Our study confirms the previous association of HLA-DR4 and HLA-DRw53 with VKH syndrome but fails
to demonstrate an association between FCRL3 polymorphisms and VKH syndrome. Haplotype CACG might be a
protective haplotype for VKH syndrome, and haplotype CGGG may be a risk haplotype in HLA-DR4 negative individuals.
Vogt-Koyanagi-Harada (VKH) syndrome is one of the
most common uveitis entities in China [1]. The major clinical
manifestations  of  VKH  syndrome  include  panuveitis,
pleocytosis in the cerebrospinal fluid, dysacusis, alopecia,
poliosis,  and  vitiligo  [2-4].  Although  the  pathogenesis  of
VKH syndrome remains uncertain, accumulating evidence
suggests  that  both  autoimmune  and  genetic  factors  are
involved in the development of this disease. Previous research
showed that VKH is a T-cell-mediated autoimmune disorder
predominantly against melanocytes [5] and that the tyrosinase
family proteins may play an important role in VKH disease.
Lymphocytes of VKH patients were shown to proliferate in
response to tyrosinase or tyrosinase related protein [6]. VKH
occurs  most  commonly  in  colored  people  such  as  certain
Asian,  American-Indian,  and  Spanish  populations  [7],
particularly in those carrying the genes coding for the human
leukocyte  antigen  (HLA),  HLA-DR4  and  HLA-DRw53
[8-10]. A study in our laboratory recently reported that the
frequencies  of  HLA-DR4  and  HLA-DRw53  were  both
significantly  increased  in  VKH  patients  (odds  ratios
[OR]=13.74 and OR=4.13, p=3.21×10–16 and p=7.08×10–5,
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respectively) [11]. However, the association between VKH
syndrome and the HLA system does not completely explain
the genetic risk for this disease. Investigation of non-HLA
susceptibility genes for VKH has been an ongoing research
subject during recent years [12].
Fc receptor-like genes (FCRLs), also known as FCRHs
(Fc receptor homology), cluster in the midst of the classical
Fc receptor genes in the human chromosome 1q21–23 region
[13]. FCRLs with similarity in structure and sequence to the
classical  Fcγ  receptor  genes  (FcγR)  contain  six
immunoglobulin  (Ig)  superfamily  members  known  as
FCRL1–FCLR6 according to their chromosomal order [14].
FCRL3 is predominantly expressed in lymphoid organs, more
precisely  in  germinal  centers,  and  has  been  linked  to  the
maturation of B cells [15]. FCRL3 may play a role in the
differentiation of B cells into autoreactive cells and has been
presumed to function through modulating signal transduction
via  activation/inactivation  of  signaling  tyrosine  protein
kinases [16]. Recently, polymorphisms of FCRL3 have been
reported  to  be  associated  with  rheumatoid  arthritis  (RA),
systemic lupus erythematosus (SLE) [17], Behcet’s disease
[18],  autoimmune  thyroid  disease  (AITD)  [17,19],  and
multiple sclerosis (MS) [20,21]. The first two have a strong
autoantibody  component  whereas  the  latter  three  are
predominately  mediated  by  T-cell  response.  As  an
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955autoimmune disease, VKH may share a common pathogenesis
with  these  autoimmune  diseases.  Therefore,  FCRL3  was
chosen as a target gene for VKH syndrome. Whether SNPs of
FCRL3 are also associated with the susceptibility to VKH
syndrome is not yet known, and this question was therefore
the subject of the study described here.
METHODS
Study participants: Patients and controls consisted of 230
Chinese VKH patients and 301 healthy controls. All control
subjects were matched ethnically and geographically with the
patients. The test subjects were recruited from the Zhongshan
Ophthalmic Center of Sun Yat-sen University (Guangzhou,
China) and the First Affiliated Hospital of Chongqing Medical
University  (Chongqing,  China).  To  exclude  the
immunogenetic  backgrounds  of  different  populations,  we
strictly chose the cases from Chinese Han descendents.
The diagnosis of VKH syndrome followed the revised
criteria for this disease [22]. The clinical characteristics of the
patients  are  presented  in  Table  1.  All  subjects  gave  their
written informed consent for this study, and the study protocol
was approved by the local institutional ethics committee.
Single nucleotide polymorphisms and genotyping: Genomic
DNA samples of VKH patients and healthy controls were
extracted and isolated from ethylene diamine tetraacetic acid
(EDTA)-anticoagulated peripheral blood mononuclear cells
(PBMCs) by a conventional salting out method and stored at
−70 °C until use.
The  four  single  nucleotide  polymorphisms  (SNPs)  in
FCRL3,  −169C/T  (rs7528684  or  fcrl3_3),  −110G/A
(rs11264799 or fcrl3_4), +358C/G (rs945635 or fcrl3_5), and
+1381A/G  (rs3761959  or  fcrl3_6),  were  genotyped  by
polymerase  chain  reaction  restriction  fragment  length
polymorphism  (PCR-RFLP).  Genotyping  of  the  −110G/A
SNP  was  performed  according  to  the  method  described
previously [23]. The primers of the three remaining loci were
designed  using  premier  5.0  software  (Premier  Biosoft
International, Palo Alto, CA). The details of the primers and
enzymes used for PCR-RFLP genotyping are presented in
Table 2.
PCR was performed in 15 μl volumes containing 7.5 μl
Premix Taq (Ex Taq Version; TaKaRa Biotechnology Co.
Ltd., Dalian, China), 0.5 μl primers (10 μmol/l), and 0.1 μg of
genomic DNA. The PCR products were then digested by the
proper restriction enzymes, separated by electrophoresis on
2%−3%  agarose  gel,  and  stained  with  GoldView™  (SBS
Genetech,  Beijing,  China).  The  images  were  recorded
digitally.  Approximately  20%  of  the  PCR  samples  were
directly  sequenced  to  confirm  the  PCR-RFLP  results
(Invitrogen Biotechnology Co., Guangzhou, China). HLA-
DR4  genotyping  was  performed  using  the  PCR  sequence
specific primers (SSP) method [24]. HLA-DRw53 typing was
performed as described previously [25].
Statistical analysis: Statistical analysis was performed with
the SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL).
The Hardy–Weinberg equilibrium (HWE) was tested by the
χ2 test. We evaluated the frequency of alleles and genotypes
TABLE 1. HLA-DR4 AND HLA-DRW53 DISTRIBUTION AND CLINICAL CHARACTERISTICS OF 230 PATIENTS WITH VKH SYNDROME.
Characteristics
VKH Patients
HLA-DR4+ n=178
(77.4%)
HLA-DR4– n=52
(22.6%)
HLA-DRw53+ n=202
(87.9%)
HLA-DRw5– n=28
(12.1%)
Male 103 (80.5%) 25 (19.5%) 116 (90.6%) 12 (9.4%)
Female 75 (73.5%) 27 (26.5%) 86 (84.3%) 16 (15.7%)
Neck stiffness 74 (72.5%) 28 (27.5%) 89 (87.3%) 13 (12.7%)
Alopecia 26 (72.2%) 10 (27.8%) 30 (83.3%) 6 (16.7%)
Poliosis 65 (73.9%) 23 (26.1%) 78 (88.6%) 10 (11.4%)
Vitiligo 41 (74.5%) 14 (25.5%) 48 (87.3%) 7 (12.7%)
Dysacusia 57 (69.5%) 25 (30.5%) 70 (85.4%) 12 (14.6%)
Tinnitus 61 (84.7%) 11 (15.3%) 67 (93.1%) 5 (6.9%)
Scalp hypersensitivity 32 (74.4%) 11 (25.6%) 38 (88.4%) 5 (11.6%)
TABLE 2. DETAILS OF THE PRIMERS, ENZYMES, AND TEMPERATURE USED IN PCR-RFLP GENOTYPING.
SNPs dbSNP ID Forward primer Reverse primer Tm (°C) Restriction enzyme
−169C/T (fcrl3_3) rs7528684 GGAAAATAATACA GGCTTTAAAA 56.9 BsmFI
    AATGTACAGATTA AACGGTGGTAC
−110A/G (fcrl3_4) rs11264799 CTCAATCCCGGT CTCATAACAAC 56.9 PleI
    AGTGATACA TTATGTGAGA
+358C/G (fcrl3_5) rs945635 TTATAGCCCATCTA CCGGGATTGAGA 60.3 HaeIII
    CTCACTCAGGATCA TACAAACAGCATTT
+1381A/G (fcrl3_6) rs3761959 TCCGACTTTTTCA TGATAGCAGCACTA 60.3 MspI
    GTCTCTAGGTTTT GCTTGGACATTCA
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956in  this  study  using  the  χ2  test  or  Fisher’s  exact  test  and
accounting for multiple testing. The haplotype frequency and
linkage disequilibrium (LD) of the SNPs were estimated with
the Haploview 3.32 program [26,27]. A haplotype frequency
less than 0.03 was not analyzed. All the data were corrected
by Bonferroni correction.
RESULTS
The  test  subjects  consisted  of  230  VKH  patients  (aged
33.4±12.6 years) and 301 healthy controls (aged 35.3±11.9
years). Of the 230 patients, 128 (55.7%) were men and 102
(44.3%) were women. No statistical difference was observed
between patients and controls in the distribution of age and
gender  (p=0.43,  p=0.82,  respectively).  All  the  cases  and
controls  were  in  Hardy–Weinberg  equilibrium  (p>0.05).
Therefore, we did the following analysis.
Four SNPs (−169C/T, −110A/G, +358C/G, and +1381A/
G) in FCRL3 were determined in all patients and controls. The
results showed that a significantly higher frequency of the G
allele at the −110 site of FCRL3 was observed in VKH patients
than in controls (p=0.0129), but this significance was lost after
the Bonferroni correction (corrected p [Pc]=0.1032; Table 3).
No significant difference was observed in the distribution of
other tested alleles or genotypes between VKH patients and
controls. The frequency of haplotype CACG was signficantly
lower  in  VKH  patients  (0.3%)  than  in  controls(3.0%;
p=0.0018,Pc=0.0288, χ2=9.77; Table 4).
We further analyzed the relationship between these SNPs
and  various  extraocular  clinical  findings  including  neck
stiffness,  tinnitus,  alopecia,  poliosis,  dysacusia,  scalp
hypersensitivity, and vitiligo. The detailed clinical findings of
the  enrolled  VKH  patients  are  shown  in  Table  1.  No
significant  difference  was  noted  between  any  clinical
parameter stated above and the investigated SNPs.
TABLE 3. FREQUENCY OF DIFFERENT ALLELES AND GENOTYPES IN FOUR FCRL3 SNPS IN VKH PATIENTS AND CONTROLS.
SNPs Patients n=230 (%) Controls n=301 (%) χ2 p value Pc OR (95% CI)
−169C/T
CC 81 (35.2) 87 (28.9) 4.7365 0.0936 NS
CT 82 (35.7) 135 (44.9) 4.7365 0.0936 NS
TT 67 (29.1) 79 (26.2) 4.7365 0.0936 NS
Alleles
C 244 (53.0) 309 (51.3) 0.3071 0.5794 NS 1.071 (0.840-1.366)
T 216 (47.0) 293 (48.7) 0.3071 0.5794 NS
−110A/G
AA 16 (7.0) 46 (15.4) 8.738 0.0127 NS
AG 81 (35.5) 98 (32.8) 8.738 0.0127 NS
GG 131 (57.5) 155 (51.8) 8.738 0.0127 NS
Alleles
A 113 (24.8) 190 (31.8) 6.174 0.0129 NS 0.707 (0.538-0.930)
G 343 (75.2) 408 (68.2) 6.174 0.0129 NS
+358C/G
CC 75 (32.6) 100 (33.4) 0.619 0.734 NS
CG 104 (45.2) 141 (47.2) 0.619 0.734 NS
GG 51 (22.2) 58 (19.4) 0.619 0.734 NS
Alleles
C 254 (55.2) 341 (55.7) 0.345 0.557 NS 0.929 (0.727-1.187)
G 206(44.8) 257 (43.0) 0.345 0.557 NS
+1381A/G
AA 135 (64.6) 150 (58.6) 8.279 0.016 NS
AG 72 (34.4) 91 (35.5) 8.279 0.016 NS
GG 2 (1.0) 15 (5.9) 8.279 0.016 NS
Alleles
A 199 (43.3) 260 (56.5) 1.356 0.5078 NS —
G 256 (42.7) 344 (57.3) 1.356 0.5078 NS
Pc: Corrected p value; NS: Not significant; OR: odds ratios.
TABLE 4. FREQUENCIES OF FCRL3 HAPLOTYPES IN VKH PATIENTS AND CONTROLS.
Haplotypes VKH 2n=456 (%)* Controls 2n=594 (%)* χ2 Fisher’s p Pc OR (95% CI)
C A C G 1.57 (0.3) 17.95 (3.0) 9.77 0.0018 0.0288 0.1 (0.02-0.59)
C A G A 78.4 (17.2) 112.0 (18.9) 0.21 0.6454 NS 0.9 (0.67-1.28)
C G C G 47.5 (10.4) 38.1 (6.4) 6.34 0.0118 NS 1.8 (1.13-2.76)
C G G A 91.1 (20.0) 116.9 (19.7) 0.14 0.7137 NS 1.1 (0.78-1.45)
T A C G 14.7 (3.2) 44.4 (7.5) 8.12 0.0044 0.0704 0.4 (0.23-0.78)
T G C G 175.4 (38.5) 219.8 (37.0) 0.81 0.3698 NS 1.1 (0.87-1.46)
The asterisk indicates that the frequency is less than 3% in both VKH cases and control.
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957HLA-DR4  and  HLA-DRw53  were  also  determined  in
VKH  patients  and  controls  using  the  PCR-SSP  and  PCR
method [24,25]. The results showed that the frequencies of
both HLA-DR4 and HLA-DRw53 were significantly higher in
VKH patients than in healthy controls (77.4% versus 19.6%,
p=7.34×10−16  and  87.8%  versus  64.1%,  p=5.59×10−10,
respectively).  Stratification  analysis  was  then  performed
according to the status of HLA-DR4 and HLA-DRw53. A
significant difference was found in the frequency of haplotype
CGGG between HLA-DR4 negative patients and HLA-DR4
negative  controls  (5.8%  versus  0%,  p=9.94×10−8,
Pc=1.59×10−6;  Table  5).  The  results  did  not  show  any
association of allele and genotype frequencies of the four
SNPs between VKH patients and normal controls following
these stratifications.
DISCUSSION
We analyzed the association of the aforementioned four SNPs
and  haplotypes  of  FCRL3  in  the  susceptibility  to  VKH
syndrome in a Chinese population. The results showed that
the frequency of haplotype CACG was significantly lower in
VKH patients and that the frequency of haplotype CGGG was
significantly higher in HLA-DR4 negative VKH patients. The
results also confirmed the association of HLA-DR4 and HLA-
DRw53  with  VKH  syndrome  as  expected.  Furthermore,
previous studies showed strong associations between FCRL3
polymorphisms  and  RA  in  Asian  groups  but  hardly  in
Caucasians [16] except a study in Spain [28], which showed
that FCRL3 polymorphisms were associated with RA after
stratification by nuclear factor kappa B1 (NF-κB1). VKH
syndrome  is  quite  common  in  both  Asian  and  Spanish
populations. The association between FCRL3 and VKH may
be of importance in Chinese VKH patients and Hispanic VKH
patients.
The test patients were strictly enrolled as VKH syndrome
patients  according  to  the  revised  criteria  [22].  As  ethnic
confounding could influence the results, we selected only
Chinese Han descendents as the test subjects. Moreover, the
healthy controls in this study were all limited to persons who
came from the same places as the patients, which avoided a
geographic bias.
As a novel immunoregulatory gene, FCRL3 has been
reported to be positively associated with various autoimmune
diseases  in  different  ethnic  populations  [17,19,21,29,30],
though certain results were conflicting [28,31]. A study by
Kochi et al. [17] in Japan found that the four SNPs of FCRL3
(−169C/T,  −110A/G,  +358C/G,  and  +1381A/G)  were
associated with RA and that SNP −169C/T was associated
with AITD and SLE. Furthermore, −169C/T SNP has been
shown to influence the level of FCRL3 expression on B cells
by altering the binding affinity of NF-κB, which appears to
play a major role in the inflammatory response according to
recent  studies  [32].  Therefore,  we  speculated  that
polymorphisms within FCRL3 could also be related to VKH
syndrome.
Although no significant differences were found in the
frequencies of the four investigated SNPs of FCRL3 between
VKH patients and normal controls, an increase trend was
observed  in  the  frequency  of  the  −110G  allele  in  VKH
patients. This result is similar to the study we recently reported
in Behcet’s disease in which only the FCRL3 −110G allele
was significantly higher in BD patients and no differences
were observed in the remaining three tested SNPs [18]. The
polymorphisms of FCRL3 were reported to be associated with
RA  in  Japan  [17,30]  and  MS  in  Spain  [20,21],  but  the
associations  could  not  be  replicated  completely  in  other
autoimmune diseases [23,33]. In the study of Graves’ disease
[19], three of the four SNPs (except −110A/G SNP) were
associated with this autoimmune thyroid disease. A study by
Japanese investigators [34] also showed that only −110A/G
SNP  was  associated  with  autoimmune  pancreatitis,  but
contrary to our result, the frequency of −110G allele was
decreased  in  these  patients.  Similar  negative  results  were
obtained for the same four SNPs of FCRL3 in other studies
concerning type 1 autoimmune hepatitis in the Japanese [35]
and SLE in the Chinese population [36]. These observations
demonstrated that the relationship between polymorphisms of
FCRL3 and autoimmune diseases is more complex than we
thought, especially in some multiple autoimmune disorders.
The further haplotype analysis showed that the frequency
of haplotype CACG was significantly lower in VKH patients.
This suggests that the haplotype CACG might be a protective
haplotype for VKH syndrome. However, the frequency of this
haplotype in patients and controls is very low (0.3% versus
3%), making it hard to make any firm conclusion on this
significance. The present results were different from those
TABLE 5. FREQUENCIES OF FCRL3 HAPLOTYPES IN HLA-DR4 NEGATIVE VKH PATIENTS AND HLA-DR4 NEGATIVE CONTROLS.
Haplotypes VKH 2n=100 (%)* Controls 2n=478 (%)* χ2 Fisher’s p Pc OR (95% CI)
C A C G 2.45 (2.5) 16.79 (3.5) 0.26 0.6102 NS 0.7 (0.18-0.74)
C A G A 16.59 (16.6) 86.29 (18.1) 0.074 0.785502 NS 0.9 (0.52-1.65)
C G C G 6.76 (6.8) 27.20 (5.7) 0.21 0.646662 NS 1.2 (0.51-2.94)
C G G A 23.80 (23.8) 94.85 (19.8) 0.987 0.320533 NS 1.3 (0.77-2.19)
T A C G 2.39 (2.4) 35.27 (7.4) 3.274 0.070433 NS 0.3 (0.08-1.18)
T G C G 33.09 (31) 182.16 (38.1) 0.704 0.401591 NS 0.8 (0.51-1.31)
C G G G 5.78 (5.8) 0.00 (0.000) 28.469 9.94e-08 5.19e-006
The asterisk indicates that the frequency was less than 3% in both VKH case and control.
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958found in BD [18] and SLE [37]. The study of BD in our
laboratory found that haplotype CGCG and TACG were both
associated with BD in which the first one was found to be
significantly higher whereas the latter was significantly lower
in BD patients as compared with healthy controls. While in
the study of SLE in Spanish individuals, only three alleles
were examined and the frequency of haplotype CGA was
found  to  be  significantly  higher  in  SLE  patients  than  in
controls.
VKH occurs most commonly in pigmented individuals
and not in whites, but interestingly, the disease is rare in
Africans [7]. It seems that the genetic background in these
individuals  rather  than  the  amount  of  pigment  is  the
predisposing factor to VKH syndrome. Various studies have
reported that HLA-DR4 and HLA-DRw53 were significantly
associated  with  VKH  syndrome  [8-10].  We  therefore
analyzed  the  association  of  the  four  SNPs  with  VKH
syndrome  based  on  the  HLA-DR4  and  HLA-  DRw53
stratification. We found that the association of HLA-DR4 and
HLA-DRw53  with  VKH  syndrome  was  extremely  strong,
which is consistent with earlier studies from China [8,38],
Japan  [10],  Korea  [39],  and  Hispanic  patients  living  in
California [40]. However, stratification analysis according to
the status of HLA-DR4 and HLA-DRw53 still showed that
none of the four SNPs was associated to VKH syndrome.
However,  the  frequency  of  haplotype  CGGG  was
significantly higher in HLA-DR4 negative patients than in
HLA-DR4 negative controls. Haplotype CGGG is probably a
risk haplotype predisposing to VKH syndrome in HLA-DR4
negative  subgroups.  The  samples  become  small  after
stratification,  consisting  of  52  HLA-DR4  negative  VKH
patients and 242 HLA-DR4 negative normal controls. The
influence of insufficient sample size can not be excluded yet.
Various studies showed that VKH shared epitopes with other
autoimmune disease-associated HLA alleles [41-43]. HLA-
DQB1, -DR1, and -DR4 all were susceptible genes for VKH
syndrome [44], and importantly, these HLA antigens were
also associated with the susceptibility to other autoimmune
diseases including type 1 diabetes [45]and Graves' disease
[46].
Systemic  disease  is  a  prominent  feature  of  VKH
syndrome.  There  is  a  large  variation  in  systemic  clinical
manifestations in Chinese VKH patients [4]. Stratification
analysis  was  therefore  performed  to  investigate  the
association  between  the  polymorphisms  of  FCRL3  and
clinical manifestations. The results showed that none of these
clinical  findings,  which  included  neck  stiffness,  tinnitus,
alopecia,  poliosis,  dysacusia,  scalp  hypersensitivity,  and
vitiligo,  was  significantly  associated  with  the  four  SNPs.
Similarly,  no  association  was  found  after  gender  and  age
stratification.
In  conclusion,  no  significant  correlation  could  be
observed  between  the  FCRL3  polymorphisms  and  VKH
syndrome in the Chinese population. Haplotype CACG might
be  a  protective  haplotype  for  VKH  syndrome.  Haplotype
CGGG is probably a risk haplotype in HLA-DR4 negative
individuals.  Similar  to  previous  studies,  we  found  strong
associations  of  HLA-DR4  and  HLA-DRw53  with  VKH
syndrome. Further studies of these SNPs and including other
variants  in  the  FCRL3  region,  using  larger  (multi-center)
patient numbers, and including various autoimmune diseases
should be performed in the future.
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